VERTEX PHARMACEUTICALS INC / MA Deferred Tax Liabilities, Net
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Deferred Tax Liabilities, Net of $9.41 million as of 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2019-02-13
- 2018-09-30: Deferred Tax Liabilities, Net $9.41M.
- 2017-12-31: Deferred Tax Liabilities, Net $5.52M.
- 2016-12-31: Deferred Tax Liabilities, Net $133.73M.
- 2015-12-31: Deferred Tax Liabilities, Net $110.08M.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2018-09-30 | $9.41M 10-Q · filed 2018-10-25 |
| 2017-12-31 | $5.52M 10-K · filed 2019-02-13 |
| 2016-12-31 | $133.73M 10-K · filed 2018-02-15 |
| 2015-12-31 | $110.08M 10-K · filed 2017-02-23 |
| 2014-12-31 | $11.54M 10-K · filed 2016-02-16 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-13 |
| 2012-12-31 | $280.37M 10-K · filed 2014-02-11 |
| 2011-12-31 | $243.71M 10-K · filed 2013-03-01 |
| 2010-12-31 | $160.28M 10-K · filed 2012-02-22 |
| 2009-12-31 | $160.28M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |